JERUSALEM, (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN) is pleased to announce that it has received approval from Israel's Ministry of Health to test the efficacy of its Deep TMS (Transcranial Magnetic Stimulation) system as a treatment for autism in children with low functionality levels. The trial, which will begin in the near future, will be conducted at Hadassah Medical Center Ein Kerem in Jerusalem and will include 40 subjects.

Uzi Sofer, Brainsway's Chief Executive Officer, commented, "While Brainsway has previously received approval for carrying out a study of our Deep TMS system together with Harvard Medical School in the United States on children with epilepsy, this will be our first clinical trial in a pediatric population in Israel."

About Brainsway Ltd.
Brainsway is dedicated to the development and marketing of Deep TMS systems - novel, noninvasive medical devices for treatment of a wide range of neurological and psychopathological disorders. In principle, any brain-related disorder that is associated with pathological activity of specific brain sites may be treated by this method.

Potential applications include addiction, schizophrenia, obesity, eating disorders, Parkinson's disease, Alzheimer's disease, obsessive-compulsive disorder, autism and post-traumatic stress disorder.

Our initial focus is the treatment of major depression. The unique technology of Brainsway is based on patents filed by the U.S. National Institute of Health (NIH) and by the company. Brainsway has an exclusive license from the NIH for the patent and technology.

Headquartered in Jerusalem, Israel, the company's ordinary shares and warrants trade on the Tel Aviv Stock Exchange under the symbol 'BRIN'.